Loading company…
Rehovot-based medical technology company whose BioTrace system predicts tissue response during ablation procedures.
TechsoMed develops BioTrace, software that provides real-time predictive visualization of tissue response during thermal ablation, mainly for liver tumor ablation and under evaluation for cardiovascular and pain management uses. It sells and licenses the technology to hospitals and healthcare providers in the United States and Japan. Founded in 2012, the company raised USD 7.00 mn in a Series B round in March 2021 led by Axil Capital Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in